Abiopharma

Clinical trial NCT05995340 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2026-08-01 → 2026-07-14 3. primary completion date: 2026-08-01 → 2026-07-14

Clinical trial NCT02687906 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2026-12-01 → 2026-07-15 3. primary completion date: 2026-12-01 → 2026-07-01

Clinical trial NCT05004337: enrollment: 126 → 136 participants.

Clinical trial NCT06101329: primary completion date: 2026-07-01 → 2026-07-22.

Clinical trial NCT07218770 updates: 1. status: ACTIVE_NOT_RECRUITING → TERMINATED 2. completion date: 2028-06-28 → 2026-07-21 3. primary completion date: 2028-06-28 → 2026-07-21 4. enrollment: 72 → 1 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT05386472: completion date: 2025-05-12 → 2025-05-13.

Clinical trial NCT06616766: enrollment: 161 → 201 participants.

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001918704-26-023862 <b>Size:</b> 706 KB

NAFDE VIKRAM A. 🟡 adjusted position in 4.8K shares of WEBSTER FINANCIAL CORP (WBS) at $79.07 Transaction Date: Aug 13, 2026 | Filing ID: 000008

Share Buy Back - Daily Share Buy-Back Notice: Share Buy-Back - Daily Share Buy-Back

SOTO JASON A. 🟡 adjusted position in 3.9K shares of WEBSTER FINANCIAL CORP (WBS) at $79.07 Transaction Date: Aug 13, 2026 | Filing ID: 000008

Schugel Jason E. 🔴 sold 830 shares of WEBSTER FINANCIAL CORP (WBS) at $79.07 Transaction Date: Aug 13, 2026 | Filing ID: 000004

Massiani Luis 🟡 adjusted position in 35.1K shares of WEBSTER FINANCIAL CORP (WBS) at $79.07 ($1.6M) Transaction Date: Aug 13, 2026 | Filing ID: 000006

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Change in Interests of Director / Chief Executive Officer - Francis Tjia

MOTL CHRISTOPHER J 🟡 adjusted position in 22.8K shares of WEBSTER FINANCIAL CORP (WBS) at $79.07 ($1.5M) Transaction Date: Aug 13, 2026 | Filing ID: 000006